Rimonabant HCl CAS NO.158681-13-1
Active Pharmaceutical Ingredients 2025-03-03
Catalog ID80017130
CAS NO.158681-13-1
Purity 98%
MDL NumberMFCD00934884
EINEC Molecular FormulaC22H21Cl3N4O.HCl
Molecular Weight500.2483
| Aspect | Details |
|---|---|
| Chemical Structure | Rimonabant HCl has the molecular formula C₂₂H₂₂Cl₄N₄O. Its IUPAC name is 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide hydrochloride. |
| Mechanism of Action | Rimonabant is a potent and selective CB₁ cannabinoid receptor antagonist. It blocks the CB₁ receptor, which is involved in regulating appetite and other behaviors. At higher concentrations, it also inhibits Gαi/o-type G proteins, resulting in a receptor-independent block of G protein signaling. |
| Clinical Uses | It was developed as an anti-obesity drug to be used in conjunction with diet and exercise for patients with a BMI greater than 30 kg/m² or those with a BMI greater than 27 kg/m² with associated risk factors such as type 2 diabetes or dyslipidemia. |
| Storage Conditions | Store at 2–8°C. |
| Pharmacokinetics | Rimonabant has a long biological half-life of 6–9 days in individuals with normal BMI and up to 16 days in those with a BMI greater than 30. It is metabolized in the liver, primarily via the CYP3A4 enzyme. |
| Side Effects | Common side effects include depression, anxiety, nausea, and dizziness. These adverse effects led to its withdrawal from the market in some countries. |
| Regulatory Status | Although it showed promise in clinical trials for weight loss and metabolic improvements, its use was restricted due to significant psychiatric side effects. |
Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.
